期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤综合治疗现状与进展

Combined therapy of multiple myeloma
下载PDF
导出
摘要 多发性骨髓瘤(MM)是浆细胞克隆增生性恶性肿瘤,其治疗效果较差,迄今仍视为不可治愈的疾病。近年来着眼于MM细胞内信号通路、骨髓微环境及二者的相互作用,MM的治疗有了很大进展。该文综述了MM的化学治疗、造血干细胞移植、生物治疗、支持治疗及免疫治疗现状及其进展。 Multiple myeloma（MM） is a kind of malignancy with plasmocyte＇s clonal hyperplasia, which have a poor therapeutic reaction, and has been regarded as an incurable malignancy . in recent years, therapy of MM gains great development because of the research to intra - cellular signal passageway, marrow microenvironment and their interaction. This article reviews current situation and recent advances about chemotherapy, hemopoietic stem cell transplant, biotherapy, supportive treatment and immunotherapy of MM.
作者 刘晓 刘巍
机构地区 河北医科大学附属第四医院肿瘤内科
出处 《现代肿瘤医学》 CAS 2007年第7期1013-1016,共4页 Journal of Modern Oncology
关键词 多发性骨髓瘤 综合治疗 multiple myeloma Combined therapy
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Myeloma Trialist Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6632 patients from 27 randomized trials[J].J Clin Oncol,1998,16:2832～2842.
  • 2Attal M,Harousseau JL,Stoppa AM,et al.A pmspective,randomized trial of autologous bone marrwo transplantation and chemotherapy in multiple myeloma[J].N Enggl J Med,1996,335:91～97.
  • 3siegel DS,Desikan KR,Mehta J,et al.Age is not a prognostic variable with auto transplants for multiple myeloma[J].Blood,1999,93:51.
  • 4Offidani M,Mele A,Corvatta L,et al.Gemeitabinealone or combined with cisplatin in relapsed or refractory multiple myeloma[J].Leuk Lymphoma,2002,43(6):1273～1279.
  • 5Aboulafia DM.Thalidomide-based treatment for HIV-aceociated multiple myeloma:a case report[J].MDS Read,2003,13(8):383～389.
  • 6Moreau P,Facon T,Attal M,et al.Comparison of 200mg/m^2 melohaant and 8Gy total body irradiation plus 140mg/m^2 melphlan as conditioning regiments for petipheral blood stemcell transplantation in patients with newly diagnosis multiple myeloma:final analysis of the intergroup Francophone du Myeloma 9502 randomized trial[J].Blood,2002,99(3):731.
  • 7Barlogie B,Shaughnessy J,Tricot G,et al.Treatment of multiple myeloma[J].Blood,2004,103:20～32.
  • 8Attal M,Harousseau J-L,Facon T,et al.Single versus double autologous stem-cell transplantation for multiple myeloma[J].New Engl J Med,2003,349:2495～2502.
  • 9Gahrton G,Svensson H,Cavo M,et al.Progress in allogeneic bone marrwo and peripheral blood stem cell transplantation for multiple myeloma:a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation Centres[J].Br J Haemato,2001,113:209～216.
  • 10Beasinger W I.Allogeneic hematopoietic cell transplantation for multiple myeloma[J].Biomed Pharmacother,2002,56(3):133～138.

二级参考文献33

  • 1Hayashi T, Hideshima, Anderson K C. Novel therapies for multiple myeloma [J]. Brit J Hematol, 2003, 120: 10-17.
  • 2Jelinek D F. Mechanism of myeloma cell growth factors [J]. Hematol / Oncol Clin N Amer, 1999, 13:1145-1162.
  • 3Chauhan D, Pandey P, Hideshima T, et al.Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- κ B [J].Blood, 1996, 87:1104-1112.
  • 4Dankbar B, Padro T, Leo R, et al. Vascular endotheliar growth factor and interleukin- 6in paracrine tumor- stromal cell interactions in multiple myeloma [J]. Blood,2000, 95:2630-2636.
  • 5Gupta D, Treon S P, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endotheliar growth factor secretion: therapeutic applications[J]. Leukemia, 2001, 15:1950-1961.
  • 6Podar K, Tai Y T, Davies F E, et al. Vascular endotheliar growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration[J]. Blood, 2001, 98:428 -435.
  • 7Davies F E, Rollinson S J, Rawstron A C, et al. High -producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increasing risk of myeloma and have an improved progressionfree survival after treatment[J]. J Clin Oncol,2000, 18:2843-2851.
  • 8Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications [J]. Oncogene,2001, 20:4519-4527.
  • 9Sati H I, Greaves M, Apperley J F, et al. Expression of interleukin 1 - α and tumor necrosis factor- α in plasma cells from patients with multiple myeloma [J]. Brit J Hematol, 1999, 104:350-357.
  • 10Costes V, Portier M, Lu Z Y, et al. Interleukin 1 in multiple myeloma: producer cells and their role in the control of IL- 6production[J]. Brit J Hematol, 1998, 103:1152-1169.

共引文献4

现代肿瘤医学
2007年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部